• 정신신체의학
• /
• 제30권2호
• /
• pp.196-202
• /
• 2022

연구목적 본 연구는 19세 남자에서 그레이브스병이 정신건강에 영향을 미치는 정도를 다면적 인성검사인 군인성검사(Military Personality Inventory, MPI) 결과를 통해 정량적으로 확인하고자 하였다. 방 법 우리는 2008년 2월부터 2010년 1월까지 병무청으로 군 신체검사를 받으러 방문한 19세 남자 중 다른 내외과 및 정신건강의학과 질환이 없는 건강한 대상자들 592명과 그레이브스병으로 확진된 대상자들 148명의 MPI 결과를 수집하고 분석하였다. 결 과 인구학적 특징에서 대상자들은 19세 남자로 나이와 성별이 동일하였으며, 교육수준, 사회경제적 상태, 부모관계, BMI 모두에서 그레이브스병 환자군과 정상대상자군 사이에 차이가 없었다(χ²=0.089, p=0.766; χ²=5.090, p=0.278; χ²=5.988, p=0.112; t=-0.635, p=0.526). 다면적 MPI 결과에서 타당도 척도에서는 긍정왜곡(fakinggood) 하위 척도 점수가 환자군에서 유의하게 낮았고(t=3.507, p<0.001), 부정왜곡(faking-bad) 하위척도 점수와 희귀도(infrequency) 하위 척도 점수는 두 군 간의 유의한 차이가 없었다(t=-1.700, p=0.090; t=-0.519, p=0.604). 신경증 척도에서는 불안(anxiety), 우울(depression), 신체화(somatization), 인격장애(personality disorder) 하위척도 점수가 모두 환자군에서 유의하게 높았다(t=-3.323, p<0.001; t=-4.210, p<0.001; t=-6.202 p<0.001; t=-2.872, p<0.01). 정신증 척도에서는 조현병 및 편집증 하위 척도 점수 모두 두 군 간의 유의한 차이가 없었다(t=-0.158, p=0.874; t=-0.846, p=0.398). 결 론 MPI 결과로 미루어 볼 때, 19세 남자에서 그레이브스병 환자는 정상대상자보다 불안 및 우울 수준이 더 높았으며, 신체적 염려 또는 증상을 더욱 호소하였고, 내향성이나 충동성과 같은 성격장애 성향이 더욱 나타났다.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1970년도 제9차 학술대회
• /
• pp.84.3-85
• /
• 1970

• Nuclear Medicine and Molecular Imaging
• /
• 제43권2호
• /
• pp.154-155
• /
• 2009

A 45-year-old man presented with fatigue and weight loss underwent a Tc-99m MDP bone scan because of increased serum alkaline phosphatase. Delayed images at 4 hours demonstrated diffuse increased activity throughout both lobes of the thyroid in the absence of activity of the stomach and salivary glands. Thyroid laboratory indices and a Tc-99m pertechnetate thyroid scan suggested Graves' hyperthyroidism.

• 대한핵의학회지
• /
• 제20권2호
• /
• pp.85-100
• /
• 1986

To evaluate the clinical and pathogenetic roles of TSH receptor antibodies in autoimmune thyroid diseases, TBII were measured by TSH-radioreceptor assay methods in 352 patients with Graves' disease, 108 patients with other thyroid diseases and 69 normal persons. The normal range of TBII activity was less than 15%. The frequencies of detectable TBII in 169 patients with untreated Graves' disease, 31 patients with hyperthyroidism under treatment and 70 patients with euthyrodism under treatment were 92.4%, 87.1% and 54.3% respectively. However 12 (21.8%) out of 55 patients who have been in remission more than one year after discontinuation of antithyroid drugs treatment had detectable TBII activities in their sera. In 196 patients with untreated Graves' disease, the frequency of TBII increased by increasing size of goiter and the frequency of proptosis was significantly high in patients whose TBII activities were more than 60%. TBII activities were roughly correlated with total $T_3,\;T_4$ and free $T_4$ index but low $\gamma^2$ value(less than 0.1). In 67 patients with Graves' disease who were positive TBII before antithyroid drugs treatment, TBII activities began to decrease from the third months and it was converted to negative in 35.8% of patients at 12 months after treatment. There were no significant differences of the declining and disappearing rates of TBII activities between high dose and conventional dose groups. TBII activities were significantly increased initially (2-4 months) and then began to decrease from 5-9 months after $^{131}I$ treatment. There were two groups, one whose TBII activities decreased gradually and the other did not change untill 12 months after subtotal thyroidectomy. Although preoperative clinical and laboratory findings of both groups were not different, TBII activities of non-decreasing group were significantly higher than those of decreasing group$(74.6{\pm}18.6%\;vs\;39.2{\pm}15.2%;\;P<0.01)$. Thirty three(55.9%) out of 59 patients with Graves' disease relapsed within 1 year after discontinuation of antithyroid drugs. The positive rate of TBII at the end of antithyroid drug treatment in relapse group(n=33) was significantly higher than those in remission group (n=26) (63.6% vs 23.1%; P < 0.05). The mean value of TBII activities at the end of antithyroid drug treatment in relapse group was significantly elevated $(29.7{\pm}21.4%\;vs\;14.7{\pm}11.1%,\;P<0.05)$. Positive predictive value of TBII for relapse was 77.8%, which was not different from those of TRH nonresponsiveness(78.6%). The frequencies of detectable TBII in 68 patients with Hashimoto's thyroiditis, 10 patients with painless thyroiditis and 5 patients subacute thyroiditis were 14.7%, 20% and 0%, respectively. However in 25 patients with primary nongoitrous myxedema, 11 patients(44%) showed TBII activities in their sera. 9 out of 11 patients who had TBII activities in their sera showed high TBII activities(more than 70% binding inhibition) and their IgG concentrations showing 50% binding inhibition of $^{125}I-bTSH$ to the TSH receptor were ranges of 0.1-2.6 mg/dl. One patient who had high titer of TBII in her serum delivered a hypothyroid baby due to transplacental transfer of maternal TBII. These findings suggested that 1) TSH receptor antibodies are closely related to a pathogenetic factor of Graves' hyperthyroidism and of some patients with primary non-goitrous myxedema, 2) measurement of TSH receptor antibodies is helpful in evaluating the clinical outcome of patients with Graves' disease during antithyroid drug treatment and in predicting the neonatal transient hypothyroidism of baby delivered from primary myxedema patients. 3) there are 2 or more different types of TSH receptor antibodies in autoimmune thyroid diseases including one which stimulates thyroid by binding to the TSH receptor and another which blocks adenylate cyclase stimulation by TSH.

• Journal of Acupuncture Research
• /
• 제40권4호
• /
• pp.377-381
• /
• 2023

This study included a 42-year-old female farmer with a 2-year history of Graves' disease who visited the hospital for a total thyroidectomy for her grade III goiter based on World Health Organization classification. Besides Hegu (LI4) and Neiguan (PC6), extensively used for acupuncture analgesia in thyroid surgery in previous studies, three additional acupuncture points for acupuncture analgesia in thyroidectomy were evaluated in this study: Shuitu (ST10), Quepen (ST12), and Yifeng (SJ17). In this case, we used an electroacupuncture stimulator to stimulate the acupuncture points and combined acupuncture analgesia with diazepam and atropine sulfate administration as adjunct medications to calm the patient. The operation was completed without any complications. The findings revealed that stimulating the five acupuncture points, i.e., Hegu (LI4), Neiguan (PC6), Shuitu (ST10), Quepen (ST12), and Yifeng (SJ17), for acupuncture analgesia combined with adjunct medications is safe for maintaining an adequate level of analgesia and hemodynamic stability during thyroidectomy.

• International journal of thyroidology
• /
• 제11권2호
• /
• pp.137-142
• /
• 2018

Background and Objectives: Radioactive iodine therapy (RAI) is an important treatment modality of Graves' disease (GD), but there is still not a consensus on the optimal dosage regimen. We studied the treatment success rate of different RAI doses, and examined which clinical markers were useful for determining the optimal RAI dosage for successful therapy in Korean patients. Materials and Methods: We retrospectively studied 123 patients with GD treated with RAI between 2004 and 2014 at Chonnam National University Hwasun Hospital. The responder group was defined as patients who developed hypothyroidism requiring levothyroxine replacement following RAI, regardless of the RAI dosage. Results: A total of 54 patients (43.9%) became hypothyroid after the first dose, and 31 needed two to four additional doses to achieve hypothyroidism. In the responder group as a whole (85 patients), the mean total dose of RAI was $15.5{\pm}7.0mCi$ and the mean thyroid volume (TV) was $35.4{\pm}23.4mL$. When divided into low dose (<15 mCi, n=46) and high dose (${\geq}15mCi$, n=39) responder groups, TV was significantly lower in the low-dose responder group ($25.7{\pm}11.4$ vs. $48.4{\pm}31.3$, p<0.001). The optimal cut-off TV for the low-dose responder group was <32.37 mL (sensitivity 80.9%, specificity 76.7%). Conclusion: TV had significant effects on the outcome of RAI in GD patients. The optimal fixed RAI dose for Korean GD patients with a large goiter (${\geq}33mL$) should be at least 15 mCi to achieve the best outcome.

• 한국방사선학회논문지
• /
• 제8권5호
• /
• pp.241-248
• /
• 2014

본 연구는 미만성 $^{18}F-FDG$ 갑상선 섭취를 보이는 PET/CT 영상에서 최대 표준섭취계수($SUV_{max}$)와 갑상선 자가 항체(anti-TPO Ab, anti-TG Ab, TSH)들 사이의 임상적 상관관계를 하시모토 갑상선염과 그레이브스병 중심으로 분석하였다. 이를 위하여 2010년 5월부터 2013년 4월까지 건강검진에서 PET/CT 검사를 시행한 환자 1,097명을 대상으로 미만성 FDG 갑상선 섭취 여부를 분석하여 갑상선 기능 검사와 초음파 검사를 추가적으로 시행하였다. 결과적으로 미만성 $^{18}F-FDG$ 갑상선 섭취를 보이는 자가 면역 갑상선 질환 환자는 39명(3.6%)이 발견되었으며 하시모토 갑상선염은 43.6%, 그레이브스병은 23.1% 이었다. 하시모토 갑상선염은 anti-TPO Ab와 anti-TG 수준이 높은 역가의 양성 반응을 보였으며 $SUV_{max}$와 anti-TPO Ab간 상관계수가 통계적으로 유의하였다(r>0.4, p<0.05). 또한 그레이브스병은 대부분의 갑상선 자가 항체의 수준이 높은 역가의 양성 반응을 보였으며 $SUV_{max}$와 TSH간 상관계수가 통계적으로 유의하였다(r>0.5, p<0.01). 따라서 미만성 18F-FDG 갑상선 섭취 증가에 따른 $SUV_{max}$ 수준이 높을수록 하시모토 갑상선염은 anti-TPO Ab 수준이, 그레이브스병은 TSH 수준이 비례적으로 증가됨을 알 수 있었고 이러한 상관관계는 자가 면역 갑상선 질환에 대한 부대 징후를 판단할 수 있는 가장 영향력 있는 척도로서 임상적 적용이 가능할 것으로 판단하였다.

• Clinical and Experimental Pediatrics
• /
• 제46권1호
• /
• pp.76-82
• /
• 2003

목 적 : 소아 Graves병의 진단 시 발병 연령에 따른 갑상선 기능, 임상 양상, 갑상선 항체가 및 치료 기간 등이 어떻게 다른지 알아보고자 본 연구를 시도하였다. 방 법 : 1989년 1월 1일부터 1995년 12월 31일까지 7년간 가톨릭대학교 의과대학 성모병원과 강남성모병원 소아과에서 Graves병으로 진단 받고 3년 이상 추적관찰이 가능하였던 환아 52명을 대상으로 Tanner의 성 성숙도를 기준으로 사춘기 이전에 발병한 군(사춘기전군)과 사춘기 시작 후 발병한 군(사춘기군)으로 나누어 갑상선 기능상태, 갑상선 항체, TSH 수용체 항체, 치료 후 갑상선 기능검사치가 정상화되는 시기 및 치료 기간 등을 조사하였다. 결 과 : 1) 전체 52명 중 남녀간의 성비는 1 : 12로 주로 여아에서 발병하였다. 2) 사춘기전군은 14명(남아 2명), 사춘기군은 38명(남아 2명)으로 각각 평균연령은 $7.2{\pm}0.9$세, $12.4{\pm}1.5$세이었다. 3) 치료 전 사춘기전군과 사춘기군에서 $T_3$는 $3.98{\pm}1.70$과 $3.82{\pm}1.63ng/mL$, $T_4$는 $17.49{\pm}5.56$과 $19.23{\pm}6.01{\mu}g/dL$, TSH는 $0.07{\pm}0.11$과 $0.07{\pm}0.24mIU/L$ 등으로 서로 유의한 차이가 없었다. 4) 치료 전 사춘기전군과 사춘기군에서 AMA 양성률은 85%와 89%이었고, 평균 항체가는 사춘기군이 사춘기전군보다 유의하게 높았다(P<0.01). ATA 양성율은 각각 57.1%와 72.2%였으나 평균 항체가의 차이는 없었으며 TBII의 양성율은 각각 92.9%와 84.2%였고 평균 항체가는 사춘기전군에서 사춘기군보다 유의하게 높았다(P<0.05). 5) 치료 후 사춘기전군과 사춘기군에서 $T_3$, $T_4$, TSH, TBII가 정상화되는 소요되는 기간은 $T_3$는 각각 $6.8{\pm}5.0$과 $5.4{\pm}13.2$개월, $T_4$는 각각 $2.3{\pm}1.9$와 $2.1{\pm}2.2$개월, TSH는 각각 $14.6{\pm}11.0$과 $6.8{\pm}7.8$개월, TBII는 각각 $26.7{\pm}24.0$과 $20.8{\pm}12.1$개월로 사춘기전군에서 TSH가 정상화되는 기간이 사춘기군보다 더 길었다(P<0.05). 두 군 모두 $T_4$, $T_3$, TSH, TBII 순으로 정상화되었다. 6) 치료 기간은 사춘기전군($53.3{\pm}19.3$개월)이 사춘기군($37.9{\pm}16.3$개월)보다 유의하게 길었다(P<0.01). 7) 약물 치료 3년 동안 관해는 사춘기전군에서 8례(57.1%), 사춘기군에서 26례(68.4%)였고 재발율은 각각 6례(75%) 및 17례(65.3%)였다. 8) Graves병의 진단 시 연령과 치료 기간 사이에는 역상관관계가 있었다(P=0.03). 결 론 : 소아에서 사춘기 이전에 발병하는 Graves병은 사춘기 이후에 발병하는 경우보다 항갑상선제 치료기간이 더 필요하다는 사실을 알 수 있었으며 앞으로 더 많은 환자를 대상으로 장기간의 연구가 필요하다고 생각된다.

• Journal of Yeungnam Medical Science
• /
• 제5권1호
• /
• pp.173-179
• /
• 1988

Since 1931, sporadic reports have appeared noting an apparent association between hyperthyroidism and idiopathic thrombocytopenic purpura. Recent various studies suggested that these two diseases may share a similar immunologic background, but the the exact mechanism is still a matter of speculation. This 22-year old female patient visisted this hospital because of general weakness and purpura of legs for 2 months. The laboratory findings were compatible with Graves' disease associated with idiopathic thrombocytopenic purpura. The palatclet count was 16000/$mm^3$, hemoglobulin was 10.9g/dl and MCV was 60.1tL. T3 was 490.53ng/dL, T4 was 24ug/dL and free T4 was 5.66ng/dL. Antiplatelet antibody and anti-microsomal antibody were positive. The bone marrow findings were compatible with tron deficiency anemia and idiopathic thrombocytopenic purpura. The thyroid biopsy showed adenomatous goiter. She was administered with propyl thiouracil, Beta-blocker, iron and prednisolon. On the 10th hospital day, platelet count was 184000/$mm^3$, hemoglobulin was 12.0gm/dL and MCV was 67.5fL. On the 20th hospital day, T4 was 10.35ug/dL and free T4 was 2.30ng/dL. Therefore she was discharged and followed up.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 2000년도 2nd Korea-China Congress of Nuclear Medicine and 39th Annual Spring Meeting if the Korea SOciety Nuclear Medicine
• /
• pp.53-53
• /
• 2000